Understanding how tumors resist treatment in lung cancer with KRAS mutations
Official title: Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
Funded at University of Tx Md Anderson Can Ctr · NIH-11077754 · Data updated 2026-11-12
This study is looking at how certain lung cancer tumors with a specific gene mutation can become resistant to treatments, and it aims to find new ways to make those treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 17, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $370,575 |
| NIH project number | 5R01CA279194-03 |
| Project ID | NIH-11077754 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer harboring KRASG12C mutations.
✕Less likely to help
Patients with non-KRAS-mutant lung cancers or those with advanced disease not amenable to targeted therapies may not benefit from this research.
What this research studies
This research investigates the mechanisms by which tumors with KRASG12C mutations develop resistance to targeted therapies in non-small cell lung cancer (NSCLC). It focuses on the interactions between tumor cells and their surrounding environment, known as the tumor microenvironment (TME), to identify factors that contribute to treatment resistance. By analyzing these interactions, the research aims to develop new strategies to enhance the effectiveness of existing therapies and improve patient outcomes. The study will also explore the role of specific genetic alterations that may influence how tumors respond to treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with KRASG12C-mutant NSCLC, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results in targeting tumor microenvironment interactions to overcome treatment resistance in various cancers, suggesting potential for success in this area as well.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Skoulidis, Ferdinandos — University of Tx Md Anderson Can Ctr
- Study coordinator: Skoulidis, Ferdinandos
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.